GlassScriptPhysician profile
Emily A Petermeier
NPI 1265028500
$1,447.33
in general payments reported to CMS, 2019-2025
22 companies · $188 in 2025
The $188 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $441 · 2022: $415 · 2023: $255 · 2024: $149 · 2025: $188.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $568 · Consulting Fee: $24.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $567.74 |
| Consulting Fee | $24.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $279.60 | 2021-2024 | Hyqvia, Gammagard |
| Daiichi Sankyo INC. | $251.08 | 2021-2023 | Injectafer |
| Astrazeneca Pharmaceuticals LP | $124.99 | 2021 | |
| Glaxosmithkline, LLC. | $124.98 | 2022 | |
| Pharmacosmos Therapeutics INC. | $124.25 | 2021 | |
| Tersera Therapeutics LLC | $64.97 | 2022-2025 | Quzyttir |
| Amgen INC. | $61.31 | 2024-2025 | Evenity, Prolia |
| Janssen Biotech, INC. | $59.02 | 2022-2025 | Stelara, Simponi Aria, Remicade |
| Sanofi-Aventis U.S. LLC | $44.12 | 2024 | |
| Genzyme Corporation | $36.83 | 2021-2022 | |
| Eisai INC. | $29.84 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.74 | 2022 | |
| Merck Sharp & Dohme LLC | $28.60 | 2023 | Recarbrio, Zerbaxa |
| Viiv Healthcare Company | $24.51 | 2022 | |
| Adma Biomanufacturing LLC | $24.42 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $23.78 | 2025 | Leqembi |
| Genentech USA, INC. | $22.95 | 2025 | Ocrevus Zunovo |
| Argenx US, INC. | $21.64 | 2025 | Vyvgart Hytrulo, Vyvgart |
| Lilly USA, LLC | $20.40 | 2024 | Kisunla |
| Horizon Therapeutics Plc | $19.92 | 2021 | |
| Abbvie INC. | $17.60 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $13.78 | 2023 | Truxima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Petermeier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.